SOD1-D91A, SOD1-D91A_K7-4Lf
ICGi022-A-2
General
Cell Line |
|
| hPSCreg name | ICGi022-A-2 |
| Cite as: | ICGi022-A-2 (RRID:CVCL_D0VS) |
| Alternative name(s) |
SOD1-D91A, SOD1-D91A_K7-4Lf
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi022-A-1 (SOD1 I114T correction (CBIGi022-A), IPSC0029) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis CBIGi001-A-19 (IPSC0084, SOD1 G93A/AIW002-02) WIBRe001-A-58 (WIBR3_VPS13C_FS_Homo_H3-1) WIBRe001-A-59 (WIBR3_VPS13C_A444P_Het_E12-1) WIBRe001-A-60 (WIBR3_VPS13C_A444P_Homo_C8-2) WIBRe001-A-5 (WIBR3_PRKN_X3DEL_F2-5) WIBRe001-A-6 (WIBR3_PRKN_X3DEL_H2-2) WIBRe001-A-7 (WIBR3_SNCA_A30P_A2-3) WIBRe001-A-8 (WIBR3_SNCA_A30P_E1-3) WIBRe001-A-9 (WIBR3_FBXO7_R498X_A7-1) WIBRe001-A-10 (WIBR3_FBXO7_FS_A3-1) WIBRe001-A-11 (WIBR3_PINK1_Q129X_C4-1) WIBRe001-A-12 (WIBR3_PINK1_Q129X_E2-2) WIBRe001-A-13 (WIBR3_PINK1_Q129X_E7-1) WIBRe001-A-15 (WIBR3_DNAJC6_c.801-2 A>G+FS/c.801-2 A>G_G12-2) WIBRe001-A-16 (WIBR3_DNAJC6_FS/FS_H10-1) WIBRe001-A-17 (WIBR3_GBA1_IVS2_G2E) WIBRe001-A-18 (WIBR3_GBA1_IVS2_E10B) WIBRe001-A-19 (WIBR3_SNCA_A53T_1) SIGi001-A-13 (iPSC0028 – MonoAllelic MAPT_Ex10+16T/Clone 1D01-11) WIBRe001-A-20 (WIBR3_SNCA_A53T_2) WIBRe001-A-21 (WIBR3_SNCA_A53T_4) WIBRe001-A-22 (WIBR3_LRRK2_G2019S_5_Het) WIBRe001-A-23 (WIBR3_LRRK2_G2019S_6_Het) WIBRe001-A-24 (WIBR3_LRRK2_G2019S_216_Het) WIBRe001-A-25 (WIBR3_LRRK2_G2019S_65_Homo) WIBRe001-A-26 (WIBR3_DJ1_X1-5DEL_2860) WIBRe001-A-27 (WIBR3_DJ1_X1-5DEL_2872) WIBRe001-A-28 (WIBR3_DJ1_X1-5DEL_2876) WIBRe001-A-74 (WIBR3_FBXO7_R498X_A7-1) BIONi037-A-2 (BIONi037-A ApoE2/2 #M10-7) WIBRe001-A-61 (WIBR3_DJ1_X1-5DEL_Het_2036) BIONi037-A-3 (BIONi037-A ApoE3/4 #P10-22) BIONi037-A-4 (BIONi037-A ApoE4/4 #I10-53) WIBRe001-A-62 (WIBR3_DJ1_X1-5DEL_Het_2038) WIBRe001-A-32 (WIBR3_EWT_S1) WIBRe001-A-63 (WIBR3_DJ1_X1-5DEL_Het_2046) WIBRe001-A-33 (WIBR3_EWT_S2) |
| Last update | 24th June 2022 |
| User feedback | |
Provider |
|
| Generator | Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG) |
External Databases |
|
| BioSamples | SAMEA9370373 |
| Cellosaurus | CVCL_D0VS |
| Wikidata | Q123032656 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Unknown
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
https://www.ncbi.nlm.nih.gov/sra/?term=SRR11413027 No disease associated mutation found |
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMN14446266 |
Ethics
Also have a look at the ethics information for the parental line
ICGi022-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | IDT crRNA and tracrRNA were used for CRISPR/Cas9 gene editing |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
ICGi022-A.
|
|
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Selection criteria for clones | ESC-like morphology |
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | |||||||||||||||
| Feeder cells |
Mouse embryonic fibroblasts Cellfinder Ont Id: http://www.ebi.ac.uk/efo/EFO_0004040 |
|||||||||||||||
| Passage method |
Enzymatically
TrypLE
|
|||||||||||||||
| O2 Concentration | 20 % | |||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||
| Medium |
Other medium:
Base medium: Knock-out DMEM
Main protein source: Knock-out serum replacement Serum concentration: 15 % Supplements
|
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
|||||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|||||
| SOX2 |
Yes |
|||||
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-60 |
Yes |
Morphology pictures
Method documentation
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.